Last $12.39 USD
Change Today -0.30 / -2.36%
Volume 40.6K
FLXN On Other Exchanges
As of 8:10 PM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).

flexion therapeutics inc (FLXN) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/6/14 - $20.85
52 Week Low
05/1/14 - $11.06
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

flexion therapeutics inc (FLXN) Related Businessweek News

No Related Businessweek News Found

flexion therapeutics inc (FLXN) Details

Flexion Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes FX006, a sustained-release intra-articular steroid, which has completed a Phase IIb dose-ranging clinical trial to treat moderate to severe osteoarthritis (OA) pain. The company is also developing FX007, a preclinical, small-molecule TrkA receptor antagonist to address post-operative pain; and FX005, a sustained-release intra-articular p38 MAP kinase inhibitor, which has completed a Phase IIa clinical trial intended as a therapy for patients with end-stage OA pain. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.

16 Employees
Last Reported Date: 05/12/14
Founded in 2007

flexion therapeutics inc (FLXN) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $437.1K
Co-Founder and Chief Medical Officer
Total Annual Compensation: $327.8K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $186.5K
Chief Business Officer
Total Annual Compensation: $178.5K
Compensation as of Fiscal Year 2013.

flexion therapeutics inc (FLXN) Key Developments

Flexion Therapeutics, Inc. Announces Board Changes

Flexion Therapeutics, Inc. announced changes to the composition of its board of directors. Sandesh (Sandy) Mahatme has been appointed to the board of directors, effective July 22, 2014. He has also been appointed as Chairman of the Audit Committee of the Board. Mr. Mahatme currently serves as Senior Vice President and Chief Financial Officer at Sarepta Therapeutics. In addition, Flexion Board member Rafaéle Tordjman, Managing Partner at Sofinnova Partners, is stepping down from the Board. Mr. Mahatme became Sarepta's Senior Vice President and Chief Financial Officer in November 2012. He is currently responsible for the finance, investor relations, facilities, IT and corporate communications functions at Sarepta.

Flexion Therapeutics, Inc. Announces Positive Topline Results from Phase 2a Pharmacokinetic Trial with Lead Compound FX006

Flexion Therapeutics, Inc. announced positive topline clinical trial results from a Phase 2a synovial fluid PK study of FX006, which demonstrated, for the first time, that a single intra-articular (IA) injection of FX006 can provide therapeutic concentrations of drug in joint fluid for at least 12 weeks. FX006 is Flexion's novel, non-opioid, sustained-release, IA formulation of TCA. It is designed to provide prolonged pain relief for the treatment of osteoarthritis (OA) of the knee, while potentially avoiding untoward systemic effects associated with immediate-release steroids. These FX006 data represent a six-fold increase in the duration of joint residency compared with immediate-release TCA, which is the current standard of care injectable therapy. It is also noteworthy that a prior PK study of FX006 demonstrated that the peak plasma concentration in the hours following injection was decreased 40-fold relative to immediate-release TCA, a decrease that may meaningfully reduce adverse systemic side effects. In this multi-center, open-label study of 50 patients with OA of the knee, researchers assigned patients sequentially to one of five groups that received a single IA injection of either 10 or 40 mg of FX006 or 40 mg of immediate-release TCA. Synovial fluid concentrations of drug were measured at 12 weeks in all dose groups and also at 16 and 20 weeks in the FX006 40 mg dose group. At 12 weeks both the FX006 10 mg and 40 mg dose groups had therapeutic concentrations of drug in synovial fluid. In contrast, the 40 mg immediate-release TCA dose group had concentrations of drug that were below the lower limit of quantitation. The FX006 40 mg dose group also demonstrated readily measurable concentrations of drug at 16 weeks, which fell to below the lower limit of quantitation at 20 weeks.

Flexion Therapeutics Announces Board Changes

On June 10, 2014, Bradley J. Bolzon notified Flexion Therapeutics, Inc. of his resignation from the board of directors of the company, effective June 11, 2014. On June 11, 2014, Elaine V. Jones notified the company of her resignation from the Board, effective immediately. On June 11, 2014, the Board, upon recommendation of the Nominating and Corporate Governance Committee of the board, elected Ann Merrifield to the board and appointed her to serve on the Audit Committee of the Board, each effective immediately. Ms. Merrifield will serve in the class of directors whose term of office expires at the Company's 2015 annual meeting of stockholders and until her successor is duly elected and qualified, or until her earlier death, resignation or removal.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FLXN:US $12.39 USD -0.30

FLXN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for FLXN.
View Industry Companies

Industry Analysis


Industry Average

Valuation FLXN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FLEXION THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at